In Brief: Taro
This article was originally published in The Tan Sheet
Executive Summary
Taro: Receives U.S. approval of ANDA for 2% miconazole nitrate vaginal cream through its subsidiary, Taro Pharmaceuticals, Inc. of Ontario, Canada. The cream, which is equivalent to Ortho's Monistat-7, will be available for private label sale within two months and also will retail under the Taro name...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
People In Brief
Perrigo promotes in pricing, planning
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: